BNP Predicts Heart Size, Function, and Death Risk in Kidney Failure Patients on Dialysis
In 112 dialysis patients, BNP was the strongest predictor of left ventricular hypertrophy and cardiac mortality, outperforming ANP and identifying the highest-risk patients for cardiovascular death.
Quick Facts
What This Study Found
BNP was the strongest predictor of left ventricular hypertrophy and cardiac mortality in 112 ESRD dialysis patients, outperforming ANP for cardiovascular risk stratification in this high-risk population.
Key Numbers
How They Did This
Cross-sectional cohort study in 112 dialysis patients. Plasma BNP, ANP, and N-terminal ANP measured. Echocardiography assessed LVH. Cardiac mortality tracked during follow-up.
Why This Research Matters
Dialysis patients have a 10-30x higher cardiovascular mortality than the general population. A simple blood test that identifies the highest-risk patients enables targeted preventive interventions.
The Bigger Picture
Cardiovascular disease causes over 50% of dialysis patient deaths. BNP-guided risk stratification could enable aggressive cardiovascular prevention in the highest-risk subset of an already high-risk population.
What This Study Doesn't Tell Us
Cross-sectional study with follow-up. Dialysis timing relative to blood sampling can affect peptide levels. Specific BNP cutoff values for this population may differ from general cardiac patients.
Questions This Raises
- ?Should BNP be measured routinely in all dialysis patients?
- ?Can BNP-guided intervention reduce cardiac mortality in ESRD?
- ?How should BNP be interpreted differently in dialysis vs non-dialysis patients?
Trust & Context
- Key Stat:
- Strongest death predictor BNP outperformed all other natriuretic peptides for predicting cardiac mortality in 112 dialysis patients
- Evidence Grade:
- Moderate evidence from a well-characterized cohort of 112 dialysis patients with echocardiographic correlation and mortality follow-up.
- Study Age:
- Published in 2001. BNP and NT-proBNP are now used in clinical nephrology for cardiovascular risk assessment in dialysis patients.
- Original Title:
- Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling.
- Published In:
- Mayo Clinic proceedings, 76(11), 1111-9 (2001)
- Authors:
- Cataliotti, A, Malatino, L S, Jougasaki, M(2), Zoccali, C, Castellino, P, Giacone, G, Bellanuova, I, Tripepi, R, Seminara, G, Parlongo, S, Stancanelli, B, Bonanno, G, Fatuzzo, P, Rapisarda, F, Belluardo, P, Signorelli, S S, Heublein, D M, Lainchbury, J G, Leskinen, H K, Bailey, K R, Redfield, M M, Burnett, J C
- Database ID:
- RPEP-00655
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Why do dialysis patients have heart problems?
Kidney failure causes fluid overload, high blood pressure, and metabolic changes that strain the heart. Over 50% of dialysis patient deaths are from cardiovascular causes, making heart monitoring critical.
How does BNP help?
A simple blood test measuring BNP identifies which dialysis patients have the most enlarged, stressed hearts and the highest risk of cardiac death. This allows doctors to intensify treatment for the highest-risk patients.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00655APA
Cataliotti, A; Malatino, L S; Jougasaki, M; Zoccali, C; Castellino, P; Giacone, G; Bellanuova, I; Tripepi, R; Seminara, G; Parlongo, S; Stancanelli, B; Bonanno, G; Fatuzzo, P; Rapisarda, F; Belluardo, P; Signorelli, S S; Heublein, D M; Lainchbury, J G; Leskinen, H K; Bailey, K R; Redfield, M M; Burnett, J C. (2001). Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling.. Mayo Clinic proceedings, 76(11), 1111-9.
MLA
Cataliotti, A, et al. "Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling.." Mayo Clinic proceedings, 2001.
RethinkPeptides
RethinkPeptides Research Database. "Circulating natriuretic peptide concentrations in patients w..." RPEP-00655. Retrieved from https://rethinkpeptides.com/research/cataliotti-2001-circulating-natriuretic-peptide-concentrations
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.